RxDoctor Payments Data

Neal Kleiman, MD

Interventional Cardiology · Houston, TXNPI 1922038298

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (38.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Medtronic at 51.5% of the total. Reporting peaked in 2019 at $31,825 and has fallen 86.4% since, to $4,337 in 2025. Among interventional cardiology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$118,488in general payments, 2019–2025

Across 426 payments — averaging $278.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$61K
  • Siemens Medical Solutions USA, Inc.$34K
  • Philips North America LLC$12K
  • Abbott$4K
  • Boston Scientific$3K
  • Edwards Lifesciences$2K
  • plus $3K from 16 others
$4,681,629in research payments, 2019–2025

Across 391 payments — averaging $11,973 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$2.7M
  • Medtronic$1.6M
  • Abbott$236K
  • Edwards Lifesciences$143K
  • Siemens Medical Solutions USA, Inc.$26K
  • Bayer$17K
  • plus $3K from 1 others

What the payments were for

  • Consulting fees$11,56310%
  • Speaking & faculty fees$45,75539%
  • Travel & lodging$35,86830%
  • Food & beverage$25,30221%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$118,488 in reported general payments places this provider in the 90th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$146,929
Medicare patients
464
Services billed
973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$138,446
EntrestoSacubitril/Valsartan86$95,285
XareltoRivaroxaban34$47,651
Repatha SureclickEvolocumab53$46,590
JardianceEmpagliflozin29$39,710
FarxigaDapagliflozin Propanediol28$21,775
Praluent PenAlirocumab22$15,958
BrilintaTicagrelor12$15,358
Ezetimibe300$9,438
VascepaIcosapent Ethyl18$8,675
Rosuvastatin Calcium365$6,450
Ranolazine ErRanolazine55$6,387
Eplerenone66$6,220
Metoprolol Succinate337$4,976
Atorvastatin Calcium361$4,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$35$95,28586 claims
Johnson & JohnsonXarelto$17$47,65134 claims
AstraZenecaFarxiga, Brilinta$338$37,13340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →